Genetically Encoded Whole Cell Biosensor for Drug Discovery of HIF-1 Interaction Inhibitors

Louis H. Scott, Mark J. Wigglesworth, Verena Siewers, Andrew M. Davis, and Florian David

ABSTRACT: The heterodimeric transcription factor, hypoxia inducible factor-1 (HIF-1), is an important anticancer target as it supports the adaptation and response of tumors to hypoxia. Here, we optimized the repressed transactivator yeast two-hybrid system to further develop it as part of a versatile yeast-based drug discovery platform and validated it using HIF-1. We demonstrate both fluorescence-based and auxotrophy-based selections that could detect HIF-1α/HIF-1β dimerization inhibition. The engineered genetic selection is tunable and able to differentiate between strong and weak interactions, shows a large dynamic range, and is stable over different growth phases. Furthermore, we engineered mechanisms to control for cellular activity and off-target drug effects. We thoroughly characterized all parts of the biosensor system and argue this tool will be generally applicable to a wide array of protein–protein interaction targets. We anticipate this biosensor will be useful as part of a drug discovery platform, particularly when screening DNA-encoded new modality drugs.

KEYWORDS: drug discovery, biosensor, new modality, genetic circuit, directed evolution, high-throughput screen

INTRODUCTION

HIF-1 is a heterodimeric transcription factor composed of HIF-1α and HIF-1β subunits that activates expression of genes for angiogenesis, glucose metabolism, cell proliferation, and metastasis in response to hypoxia.1 HIF-1 is overexpressed in many cancers, leading to intratumoral adaptation to hypoxia and resistance to cancer treatments.1 Manipulation of HIF-1 expression has shown beneficial effects on tumor growth, making it a good target to drug in combination therapies.2 Nevertheless, few traditional small molecule drug discovery efforts have provided leads against HIF-1 dimerization,3 let alone generated clinically available drugs.4 The importance of HIF-1 in cancers, compounded with difficulties in finding specific inhibitors, provides a strong impetus to explore alternative drug discovery approaches to use against HIF-1.

New modality therapeutics, such as peptides, RNA therapeutics, protein degraders and antibody conjugates offer an innovative solution against hard to hit targets, such as protein–protein interactions (PPIs) like HIF-1.5 Discovery of these biology-based therapeutics can be supported by synthetic biology approaches, where living systems are engineered to not only produce new chemical diversity but also to discern functionality using genetic screens.6 While assays for drug discovery against HIF-1 have been engineered in different mammalian cell lines,7,8 their use is limited when compared to implementations in simpler organisms such as bacteria or yeasts that can also be efficiently engineered to display tens of millions of new modality therapeutic variants. For example, engineered bacteria were used to screen libraries of genetically encoded cyclic peptides against a variety of PPI targets, including HIF-1.9–11

The yeast Saccharomyces cerevisiae has advantages over bacteria as a drug discovery tool. It is evolutionarily closer to humans, meaning any finding should translate better into the clinic;12 yeast can glycosylate proteins, which enables it to mimic human targets with better fidelity;13 and efforts are underway to humanize yeast.14 Yeast can also produce a wide array of compounds, and many characterized genetic parts can be combined to screen a variety of molecules for drug leads.15 Testament to the power of yeast, it is the archetypical system for studying PPIs using the yeast two-hybrid system (YTH).16 Here, if two proteins interact, they induce the expression of a reporter gene by creating an artificial transcription factor.

While this assay was used to identify HIF-1 effectors, it is neither versatile nor robust. It cannot be adapted to investigate other PPIs as it requires cognate HIF-1 cognate binding motif.16

Received: May 23, 2022
Published: October 12, 2022
tally, the YTH system is not suited to discover PPI inhibitors as it lacks a positive selection, as desired compounds do not cause reporter gene expression.

A clever variation of the yeast two-hybrid system, the repressed transactivator (RTA) yeast two-hybrid biosensor system, was engineered as a drug discovery screen to identify small molecule protein interaction inhibitors.17,18 Here, when two proteins interact, they repress the expression of a reporter gene. The reporter gene is only then expressed if a compound prevents the PPI, thus providing a positive selection for PPI inhibition and making the selection for potential false positives less likely. The RTA system however relies on growth as readout, which is difficult to precisely quantify, thus making ranking of relative drug potency inaccurate. Furthermore, no mechanisms to control for drug off-target effects are in place, leading to potential false-positives that could quickly overgrow a culture if growth is used as selection. Addressing these issues should provide a more robust assay, thus reducing potential drug candidate attrition.

We wanted to expand the RTA system as a versatile yeast-based drug discovery tool and then validate it using HIF-1 as the target. To do this, we explored the use of fluorescence as reporter output to enable fluorescent activated cell sorting (FACS) to be used in conjunction with growth selection, which is more suitable as a prescreening step. Additionally, we thoroughly characterized all individual parts in the sensor, and where possible, we used orthogonal systems to those endogenous to yeast. Furthermore, we engineered an internal control for biosensor cell health and an additional control strain to detect false positives. Using our optimized RTA system, we show fluorescence output and growth selection for the biosensor strain when HIF-1α/HIF-1β dimerization is inhibited, establishing this new tool as an important element in future drug discovery platforms.

II RESULTS

Design and Construction of a Protein–Protein Interaction Inhibitor Biosensor with Fluorescence Output. A schematic describing the expanded RTA system designed in this study specifically to detect HIF-1α/HIF-1β dimerization inhibitors is found in Figure 1. Briefly, a transcripional activator fused to a bait protein (HIF-1α) will induce expression of a reporter gene when targeted to it via DNA binding domains. When a prey protein (HIF-1β) is coexpressed as a fusion to a transcriptional repressor, it will turn off the reporter gene through bait–prey interaction. The reporter gene is only then turned back on when a compound (e.g., small molecule) inhibits the bait–prey PPI. Details describing specific parts redesigned in this study are outlined in the following sections.

We chose the enhanced green fluorescent protein (EGFP)19 as a FACS-compatible reporter gene. Additionally, we chose the bacterial DNA-binding protein LexA20 to interact with the reporter gene promoter as an orthogonal solution to the GAL system used in the previous setup.21 Using these parts, we explored whether a genetic configuration could lead to high reporter gene expression, yet would also be sensitive to transactivation. We genomically integrated cassettes with either two, four, or eight lexA operators20 upstream of the minimal CYC1 promoter (pCYC1min) to drive EGFP expression (lexABox2-pCYC1min-EGFP, lexABox4-pCYC1min-EGFP, or lexABox8-pCYC1min-EGFP). In these strains we also coexpressed a LexA-based22 transactivator comprised of the full length lexA Box-

![Figure 1. Representation of the repressed transactivator two-hybrid system adapted to detect inhibitors of HIF-1α/HIF-1β dimerization by fluorescence. (A) In the absence of the transactivator, the reporter gene (EGFP) is not transcribed. (B) Fusion of bait protein (HIF-1α) with the transactivator (LexA-VPR-SV40) causes expression of EGFP via interaction with lexA operators (lexA Box) upstream of the minimal CYC1 promoter. (C) A fusion of the transcripional repressor (Tup1-SV40) and prey protein (HIF-1β) will interact with the bait (HIF-1α) and cause repression of EGFP expression. (D) Inhibition of HIF-1α/HIF-1β dimerization (e.g., via an additional HIF-1α subunit) causes reporter derepression and results in expression of EGFP. SV40 = nuclear localization sequence (NLS).](image-url)
biosensor should be most responsive to inhibitors when its parts are least abundant, we continued biosensor testing with the strain expressing the transactivator–bait fusion from the REV1 promoter. We next investigated if a PPI could recruit a transcriptional repressor to our reporter gene, thus turning it off. As HIF-1 is a heterodimer of HIF-1α/HIF-1β, we expressed HIF-1β as prey while fused to an NLS and either of the transcriptional repressors: Tup1 (N-terminal repression domain), Mig1, or Mxi1 (N-terminal repression domain). We expressed these repressor fusions from either the RNR2 or REV1 promoters in the reporter strain (lexA4-pCYC1min-EGFP) coexpressing the transactivator–bait (LexA-VPR-HIF-1α) from the REV1 promoter. When measuring reporter gene fluorescence by flow cytometry (Figure 2C), we found Tup1 to provide the best transcriptional repression, and that repression increased with repressor–prey expression. These results indicate that repression of reporter gene expression is caused by bait–prey interaction.

Validation of the Fluorescent RTA Biosensor. From our results characterizing the reporter gene, transactivator–bait, and repressor–prey fusions, we deemed a system with four lexA operators (lexA4-pCYC1min-EGFP), expressing the VPR transactivator-HIF-1α from the REV1 promoter, and the Tup1 repressor-HIF-1β fusion from the RNR2 promoter would be a suitable biosensor configuration. With this configuration, the biosensor is in a repressed “OFF” state and only outputs 14% of the maximal fluorescence when compared to reporter gene transactivation solely from LexA-VPR-HIF-1α (Figure 2D). We next needed to validate if

---

Figure 2. Design and construction of a protein–protein interaction biosensor with fluorescence output. (A) Fluorescence (GFP) output from reporter genes (with either 2, 4, or 8 lexA operators) with or without coexpression of the LexA-VP16 transactivator from the ADH1 promoter. (B) Fluorescence (GFP) output from the reporter gene lexA4-pCYC1min-EGFP in cells coexpressing transcriptional activators (either LexA-VP16 or LexA-VPR) fused to the bait protein HIF-1α. Transcriptional activator–bait fusions were expressed from different promoters as denoted on the x-axis. (C) Transcriptional repression of the reporter gene lexA4-pCYC1min-EGFP in cells coexpressing the transactivator–bait (LexA-VPR-HIF-1α) from the REV1 promoter, along with various repressor–prey proteins (Tup1-HIF-1β, Mig1-HIF-1β, or Mxi1-HIF-1β) as denoted on the x-axis. Repressor–prey proteins were expressed from either the RNR2 or REV1 promoter. (D) Dynamic range of the biosensor. Fluorescence (GFP) output is shown as maximal reporter gene (lexA4-pCYC1min-EGFP) output (AD-HIF-1α), repressed “OFF” state output (AD-HIF-1α + RD-HIF-1β), and derepressed “ON” state output (AD-HIF-1α + RD-HIF-1β + HIF-1β). Biosensor derepression is achieved when an additional HIF-1β subunit is coexpressed. Additionally, fluorescence output from the reporter gene lexA4-pCYC1min-EGFP in cells coexpressing the transactivator–repressor fusion (AD-RD) from the REV1 promoter is shown as a midway “MID” state. The output of the sensor in either “OFF”, “ON”, or “MID” states is shown as a percentage of the original biosensor fluorescence. (E) Time course study of the dynamic range of the biosensor. Fluorescence output relative to biomass for strains described in panel D was measured over time. Bars represent mean values, and error bars represent the standard deviation. (F) Fluorescence (GFP) output of the biosensor reporter gene (lexA4-pCYC1min-EGFP) relative to constitutive mRFP670 expression. GFP fluorescence of the biosensor strain in the “OFF” state (AD-HIF-1α + RD-HIF-1β) increases relative to mRFP670 fluorescence in the “ON” state when coexpressing an additional HIF-1β subunit (AD-HIF-1α + RD-HIF-1β + HIF-1β). For panels D–F, AD = LexA-VPR, RD = Tup1, and AD-RD = LexA-VPR-Tup1.
inhibition of HIF-1α/HIF-1β dimerization could be registered as an increase in fluorescence output from this "OFF" state. We expressed an additional HIF-1β subunit from a centromeric plasmid using the TEF1 promoter in this biosensor strain. We observed derepression of the reporter gene by flow cytometry, presumably caused by competitive binding of the additional HIF-1β subunit to the transactivator-HIF-1α (Figure 2). The sensor in this "ON" state returned to 95% of the maximal fluorescence output when compared to reporter gene transcription solely from LexA-VPR-HIF-1α (Figure 2D). As the HIF-1α/HIF-1β Per-Arnt-Sim (PAS) B domain interaction $K_D$ is 378 nM, the sensor should therefore be sensitive enough to detect inhibitors close to this potency.

Our previous results imply that the reporter gene is sensitive to the interplay between transactivator-bait and repressor-prey expression. As these parts are driven by endogenous promoters that may up- or down-regulate throughout different growth stages in a batch cultivation, we did a time course study to measure the fluorescence response of the biosensor to an additional HIF-1β subunit. We found the biosensor to be most responsive from 6 to 18 h, during which the largest differences in fluorescence between "ON" and "OFF" states were recorded (Figure 2E). Overexpression of the additional HIF-1β subunit caused a slight growth defect (Figure S3); however, this did not translate into lower relative fluorescence (Figure S4).

It is possible that reporter gene expression in the biosensor is repressed through overexpression of Tup1 and not because of recruitment of the repressor-prey protein. To investigate this, we replaced wild-type HIF-1α with a dimerization weak mutant, HIF-1αmut (Q320E, V336E, and Y340T), as transactivator-bait fusion in the biosensor strain. This transactivator should only weakly recruit the repressor-prey fusion, resulting in less reporter gene repression. We found the biosensor with mutant HIF-1α displayed significantly less reporter gene repression (39% of the maximal output) when compared to the wild-type transactivator-HIF-1α strain (14% of the maximal output) (Figures S1 and 2D). We next removed the HIF-1α bait from the transactivator fusion in the biosensor strain (while still retaining expression of the repressor-HIF-1β fusion). Although reporter gene expression decreased slightly (only down to 71% of the maximal output) in this variant, this decrease was significantly less than observed when both interacting bait and prey fusions were present (down to 14% of the maximal output) (Figures S2 and 2D). Together, these results indicate reporter gene expression is predominately dependent on PPI and that inhibition of PPI can be selected for using fluorescence.

**Biosensor Controls for Biological and off-Target Effects.** The biosensor output could be affected by biological distortions related to cell size and growth, or by off-target and pleiotropic effects from screened drugs. To mitigate this, we integrated a cassette expressing miRFP670 under control of the constitutive TEF1 promoter to provide a red fluorescence signal to normalize the GFP output of the biosensor strain with. Derepression of this biosensor from "OFF" to "ON"
states, achieved by coexpressing an additional HIF-1α subunit, is observed as an increase in GFP expression relative to miRFP670 (Figure 2F).

In parallel, we engineered an additional biosensor strain to counter-screen against false-positive signals that could arise if a drug has off-target effects, for example by binding to the repressor and inactivating it. In this strain, the protein-interacting partners were omitted, leaving a fusion of LexA-VPR-Tup1. When recruited to the lexA-controlled reporter gene, the signal strength is midway “MID” between the fully activated and fully repressed biosensor, achieving only 37% of the maximal reporter gene output (Figure 2D). Here, if a drug inactivates the repressor, thus giving a false positive signal in the primary screen, we should be able to discern this as an increase in fluorescence.

**Design and Construction of a Protein-Protein Interaction Inhibitor Biosensor with Auxotrophic Selection.** The original RTA sensor system uses auxotrophy as selection, a powerful way to quickly screen large libraries without limitations of FACS throughput. Unfortunately, auxotrophic output is generally binary, where cells grow or not, making the relative assessment of selected inhibitor potency difficult. We reasoned instead that auxotrophic selection would be better suited as a prescreening step used in conjunction with FACS to decrease the number of library members before more detailed investigation of potency via fluorescence.

To take advantage of growth selection as a prescreen step, we integrated a cassette expressing HIS3 from the minimal CYC1 promoter controlled by two lexA operators (lexAx2-pCYC1min-HIS3) into histidine auxotrophic yeast strains also engineered with various parts of the biosensor (combinations of reporter gene, transactivator—bait, and repressor—prey). We found the strain expressing the HIS3 reporter, additional to the EGFP reporter and the transactivator—bait, grew similarly to the strain also coexpressing the repressor—prey, indicating that the HIS3 reporter gene was not repressed enough to prevent growth in media lacking histidine (Figure 3A).

We made additional variations of the HIS3 reporter gene in an effort to lessen leaky expression based on strategies to decrease transcription and/or translation. First, we retained the two lexA boxes in the reporter gene promoter region but replaced the native HIS3 ATG start codon with the rare TTG variant (lexAx2-pCYC1min-ttg-HIS3). We also engineered a reporter gene with only a single lexA operator and mutated the Kozak consensus region to hexa-cytosine (lexAx1-pCYC1−min-cccccc-HIS3). We found the strain with the TTG start codon could not survive in media lacking histidine when only the transactivator—bait was coexpressed, indicating HIS3 expression was too low in this variant (Figure 3C). We found however that the variant with one lexA box and the deoptimized Kozak sequence grew in media lacking histidine when only coexpressing the transactivator—bait yet did not survive when also coexpressing the repressor—prey (Figure 3B). This result suggests that the HIS3 gene is repressed enough to allow selection for HIF-1α/HIF-1β dimerization inhibitors.

To validate the auxotrophic selection, we expressed an additional HIF-1β subunit from a centromeric plasmid using the TEF1 promoter in the biosensor strain also harboring the lexAx1-pCYC1min-cccccc-HIS3 reporter gene. We observed derepression of both fluorescent and auxotrophic reporter genes (Figure 3D,E), indicating both selection mechanisms were functional within the same strain.

**DISCUSSION**

As protein-based new modality drugs can be DNA encoded, it stands to reason to use cells as living factories to produce them, enabling the display of tens of millions of drug variants simply by expressing a DNA library. However, this strategy is limited by traditional high-throughput screening protocols that can assay only hundreds of thousands of variants. A solution is to use an internal selection mechanism within every drug-producing cell, enabling the producer cell to also decipher whether it has made a functional drug variant. Such a selection would need to meet throughput demands yet also provide a sensitive readout related to potency. This work presents an addition to the genetic selection toolbox intended to address these issues.

Fundamental to any engineering discipline, the biosensor presented is modular, easy to engineer, allows rapid prototyping, and behaves in a predictable manner. We designed and built the optimized RTA biosensor with a plug-and-play mindset by adopting the yeast modular cloning toolkit assembly method. Biosensor parts can be easily combined to express many target variants, at differing expression levels, when fused to transcriptional activators and repressors of choice. Furthermore, recent toolkit developments facilitate these constructs to be directly integrated into desired genomic locations. We also observed a clear relationship between part and function (e.g., transcriptional activator strength and fluorescence signal), giving predictability to the system as well as future-proofing it. Our system should therefore be open to new parts as they become characterized. Future work should explore other transcriptional repressors, possibly by combining repression domains, as we did not see strong repression using Mxi1 or Mig1 as reported elsewhere. More efficient repression of the system would provide a larger dynamic range. Ultimately, statistical modeling could inform part choice for finely tuned sensors intended for specific applications.

The biosensor provides an output that is stable, tunable, able to be interpreted easily with general laboratory methods, and with high dynamic and operational range. It could discern between strong and weak interacting partners, making the system a useful way to select for relative drug potency. While the biosensor could detect a nM binder (HIF-1β subunit PASB domain), it was not fully activated (albeit close to 100%), suggesting the limit of detection may be lower. Future work should relate binding kinetics with sensor output to better gauge sensor sensitivity. Additionally, existing cyclic peptide inhibitors with known potency against HIF-1 should be expressed in the sensor strain to ascertain limits of detection and would be an important first step should this sensor be used to display peptide variants. Ultimately this assay is more intended as a primary screen from which the most potent hits would be channeled into a secondary biophysical assay for further characterization.

The sensor is also stable, likely owing to the genomic integration of all biosensor parts, whereas previous iterations mostly used episomal expression. Furthermore, it has a large operational window, important as an inhibitor made in vivo may need time to accumulate within the cell to a functional concentration. Care should be taken to express any genetically encoded modalities using a promoter similar to, or stronger
than, the TEF1 promoter (used to express the HIF-1/β subunit during validation) to ensure accumulation of therapeutics to a functional concentration.

While fluorescence output is a relative way to measure potency, retaining auxotrophic selection was an important design choice. High-efficiency yeast transformation enables the construction of libraries with 10¹⁶ members, a number greater than can be practically screened by FACS. Magnetic-activated cell sorting is a solution for this in antibody display projects; we argue, however, that library diversity can be significantly lowered using a far simpler life-or-death prescreening strategy that does not require additional laborious materials or protocols. By limiting auxotrophic selection to a prescreening step, the potential growth of false-positive or escape mutants that could overgrow the culture of desired drug variants is restricted.

A major advantage our system offers is the ability to normalize the output signal to cellular activity or health. While a drug may have a negative effect on cell health, it may still bind the intended target. In such a scenario, the GFP output may be low, yet this would be considered a positive signal if it was high relative to mRFP670. Such a hit could offer a functional starting point from which medicinal chemistry could optimize specificity.

An obstacle with any screening strategy is overcoming off-target effects that produce a false-positive signal. Particularity for hard to hit targets, where the interface of protein dimers may not contain many druggable pockets, the likelihood of selecting an off-target hit might indeed be more probable. For example, this could be a hit binding the repressor and rendering it nonfunctional, or binding the activator and increasing its activity. To mitigate this risk, the control biosensor strain would act as a counter-screen to use against short-listed hits from the primary screen. Having a counter-screen in a separate strain also controls for biosensor escape mutants. Here, a nonsense mutation in the repressor or a mutation in one of the targets making them weakly interact will be registered as a positive signal in the primary screen, but as a negative signal in the secondary screen. Interestingly, the biosensor with bait and prey interaction showed greater difference could be explained by steric hindrance where the HIF-1 dimer might shield the activation domain from recruiting coactivators.

In conclusion, we have engineered a variation of the RTA biosensor system to enable both fluorescence and auxotrophic selections. The biosensor is constructed in a modular fashion, meaning it should be applicable to other PPI targets of interest. Additionally, we provide an option to control for off-target effects and the ability to screen for false-positives. We anticipate this biosensor will be useful as part of a drug discovery platform, particularly when screening DNA-encoded new modality drugs.

**MATERIALS AND METHODS**

**Bacterial Strains and Growth.** All plasmids were cloned and amplified in competent DH5α Escherichia coli cells. E. coli was cultured in lysogeny broth (LB) (10 g/L tryptone, 5 g/L yeast extract, 5 g/L NaCl, 5 mL/L 1 M Tris–HCl, and 20 g/L agar for solid media) and supplemented with appropriate antibiotics (ampicillin 100 mg/mL or chloramphenicol 34 mg/mL). E. coli was cultured at 37 °C, with shaking at 200 rpm for liquid cultures.

**Yeast Strains and Growth.** Saccharomyces cerevisiae CEN.PK 102-5B (MATa ura3-52 his3Δ1 leu2-3/112 MAL2-8′SUC2) was used as background for biosensor strain construction. S. cerevisiae was routinely cultured on yeast peptone dextrose (YPD) medium (10 g/L yeast extract, 20 g/L peptone from casein, 20 g/L glucose, and 20 g/L agar for solid media) supplemented with appropriate antibiotics (Nourseothricin, 100 mg/L and Geneticin, 200 mg/L). Synthetic complete dextrose (SD) media (6.7 g/L yeast nitrogen base without amino acids, 20 g/L glucose, 0.79 g of complete supplement mixture, and 20 g/L agar for solid media) was used to maintain plasmids in yeast. Depending on selection, uracil or histidine were omitted. Yeast was cultured at 30 °C and with shaking at 220 rpm for liquid cultures. Yeast was routinely transformed by chemical transformation following the lithium acetate protocol.

**Growth Profiler.** Time course measurement of yeast growth was monitored using a growth profiler (EnzyScreen). Yeast strains were inoculated from 24 h precultures to an OD₆₀₀ 0.1 in 250 μL of media. Cultures were grown at 30 °C with shaking at 250 rpm in a 96-well microtiter plate. A minimum of three biological replicates were used per measurement. Data analysis and figure creation were done with GraphPad Prism software.

**Plasmid and Strain Construction and Verification.** Plasmids were constructed using either Gibson assembly (Gibson Assembly Master Mix, New England Biolabs), Golden Gate assembly, or restriction ligation as per published protocols. Routine DNA sequence verification was done by Eurofins Genomics. Plasmid and gel extraction kits from Thermofisher Scientific were used to purify DNA for cloning. Polymerase chain reactions (PCR) were performed using Phusion DNA polymerase (ThermoFisher Scientific) for cloning. Yeast codon optimized genes were synthesized at either GenScript, Integrated DNA Technologies, or TWIST bioscience. Details of plasmids constructed in this study can be found in the supplementary sequences and strains file in the Supporting Information.

The EasyClone-MarkerFree strategy was used to genomically integrate expression cassettes into yeast. Integrative cassettes were either prepared as per the EasyClone-MarkerFree strategy or amplified by PCR from plasmids with oligonucleotides found in Table S1 that provide homology to genomic sites. Genomic DNA was extracted from yeast by boiling colonies in 20 nM NaOH for 5 min, and 0.5 μL was used as a template to confirm genomic integrations by colony PCR as per the EasyClone-MarkerFree strategy, or as template for plasmid parts. Colony PCR was performed using SapphirAmp as per the manufacturer’s protocol. The genotype of strains constructed in this study can be found in the supplementary sequences and strains file in the Supporting Information.

**Fluorescence Measurement.** Real-time fluorescence was measured using a BioLector (m2p-laboratories GmbH, Baesweiler, Germany). Yeast strains were inoculated from 24 h old precultures to a starting OD₆₀₀ of 0.1 in 1 mL of media in 48-well FlowerPlates. GFP expression was measured as a ratio of GFP fluorescence to biomass. A minimum of three biological replicates were used per measurement. Data analysis and figure creation was done with GraphPad Prism software.

Flow cytometry was undertaken using a Guava easyCyte 8HT system (Merck Millipore). Yeast strains were inoculated from 24 h old precultures to a starting OD₆₀₀ of 0.1 in 250 μL...
of media in a 96-well microtiter plate and grown for 16 h in a growth profiler (EnzyScreen). Yeast cultures were then diluted to an OD<sub>600</sub> of 0.02 in 200 µL of water and fluorescent proteins excited with a 488 nm laser (for GFP) or 648 nm laser (for mIRFP670). 5000 events were recorded per sample. A minimum of three biological replicates were used per measurement. Fold over background fluorescence was calculated as the fold change in median fluorescence compared to the background yeast strain CEN.PK 102-5B. Data analysis and figure creation was done with GraphPad Prism and FlowJo software.

**ASSOCIATED CONTENT**

*Supporting Information*

The Supporting Information is available free of charge at https://pubs.acs.org/doi/10.1021/acssynbio.2c00274.

biosensor output with dimerization weak or absent protein targets (Figures S1 and S2); growth curves for biosensor strains (Figure S3); fluorescence output of biosensor strains (Figure S4); oligonucleotides used in this study (Table S1) (PDF)

Genotype and sequences of strains constructed (XLSX)

**AUTHOR INFORMATION**

**Corresponding Author**

Florian David — Department of Biology and Biological Engineering, Division of Systems and Synthetic Biology, Chalmers University of Technology, SE-41296 Gothenburg, Sweden; Email: davidfl@chalmers.se

**Authors**

Louis H. Scott — Discovery Sciences, Biopharmaceuticals R&D, AstraZeneca, SE-41320 Gothenburg, Sweden; Department of Biology and Biological Engineering, Division of Systems and Synthetic Biology, Chalmers University of Technology, SE-41296 Gothenburg, Sweden; orcid.org/0000-0001-8436-5151

Mark J. Wigglesworth — Discovery Sciences, Biopharmaceuticals R&D, AstraZeneca, Alderley Park SK10 2NA, U.K.

Verena Siewers — Department of Biology and Biological Engineering, Division of Systems and Synthetic Biology, Chalmers University of Technology, SE-41296 Gothenburg, Sweden

Andrew M. Davis — Discovery Sciences, Biopharmaceuticals R&D, AstraZeneca, Cambridge CB2 0AA, U.K.

Complete contact information is available at: https://pubs.acs.org/10.1021/acssynbio.2c00274

**Author Contributions**

L.H.S., M.J.W., V.S., A.M.D., and F.D. conceived the project and designed the research. L.H.S. performed the experiments and analyzed the results. L.H.S wrote the manuscript. All authors discussed the results and reviewed the manuscript.

**Notes**

The authors declare no competing financial interest.

**ACKNOWLEDGMENTS**

This work was supported by a grant from Sweden’s Innovation Agency Vinnova. L.H.S. is funded through the AstraZeneca Postdoctoral Programme. We thank Michael Gossing for helpful discussions.

**REFERENCES**

(1) Semenza, G. L. HIF-1 Mediates Metabolic Responses to Intratumoral Hypoxia and Oncogenic Mutations. *J. Clin. Invest.* 2013, 123 (9), 3664–3671.

(2) Semenza, G. L. Targeting HIF-1 for Cancer Therapy. *Nat. Rev. Cancer* 2003, 3 (10), 721–732.

(3) Lee, K.; Zhang, H.; Qian, D.; Z.; Rey, S.; Liu, J. O.; Semenza, G. L. Acriflavine Inhibits HIF-1 Dimerization, Tumor Growth, and Vascularization. *Proc. Natl. Acad. Sci. U. S. A.* 2009, 106 (42), 17910–17915.

(4) Bhattachari, D.; Xu, X.; Lee, K. Hypoxia-Inducible Factor-1 (HIF-1) Inhibitors from the Last Decade (2007 to 2016): A “Structure–Activity Relationship” Perspective. *Med. Res. Rev.* 2018, 38 (4), 1404–1442.

(5) Valeur, E.; Guéret, S. M.; Adihou, H.; Gopalakrishnan, R.; Lemurell, M.; Walldman, H.; Grossmann, T. N.; Plowright, A. T. New Modalities for Challenging Targets in Drug Discovery. *Angew. Chem., Int. Ed.* 2017, 56 (35), 10294–10323.

(6) David, F.; Davis, A. M.; Gossing, M.; Hayes, M. A.; Romero, E.; Scott, L. O.; Wigglesworth, J. M. A Perspective on Synthetic Biology in Drug Discovery and Development-Current Impact and Future Opportunities. *SLS Discovery Adv. Life Sci. R D 2021*, 26 (5), 581–605.

(7) Hsu, C.-W.; Huang, R.; Khuc, T.; Shou, D.; Bullock, J.; Grooby, S.; Griffin, S.; Zou, C.; Little, A.; Astley, H.; Xia, M. Identification of Approved and Investigational Drugs That Inhibit Hypoxia-Inducible Factor-1 Signaling. *OncoTarget* 2016, 7 (7), 8172–8183.

(8) Lee, K.; Qian, D. Z.; Rey, S.; Wei, H.; Liu, J. O.; Semenza, G. L. Anthraclytone Chemotherapy Inhibits HIF-1 Transcriptional Activity and Tumor-Induced Mobilization of Circulating Angiogenic Cells. *Proc. Natl. Acad. Sci. U. S. A.* 2009, 106 (7), 2353–2358.

(9) Tavassoli, A.; Lu, Q.; Gam, J.; Pan, H.; Benkovic, S. J.; Cohen, S. N. Inhibition of HIV Budding by a Genetically Selected Cyclic Peptide Targeting the Gag–TSG101 Interaction. *ACS Chem. Biol. 2008*, 3 (12), 757–764.

(10) Miranda, E.; Nordgren, I. K.; Male, A. L.; Lawrence, C. E.; Hoakwiev, F.; Cuda, F.; Court, W.; Fox, K. R.; Townsend, P. A.; Packham, G. K.; Eccles, S. A.; Tavassoli, A. A Cyclic Peptide Inhibitor of HIF-1 Heterodimerization That Inhibits Hypoxia Signaling in Cancer Cells. *J. Am. Chem. Soc.* 2013, 135 (28), 10418–10425.

(11) Tavassoli, A.; Benkovic, S. J. Genetically Selected Cyclic Peptide Inhibitors of AICAR Transformylase Homodimerization. *Angew. Chem., Int. Ed. Engl.* 2005, 44 (18), 2760–2763.

(12) Hughes, T. R. Yeast and Drug Discovery. *Funct. Integr. Genomics* 2002, 2 (4–5), 199–211.

(13) Wildt, S.; Gerngross, T. U. The Humanization of N-Glycosylation Pathways in Yeast. *Nat. Rev. Microbiol.* 2005, 3 (2), 119–128.

(14) Laurent, J. M.; Young, J. H.; Kachroo, A. H.; Marcotte, E. M. Efforts to Make and Apply Humanized Yeast. *Brief. Funct. Genomics* 2016, 15 (2), 155–163.

(15) Lentze, N.; Auerbach, D. The Yeast Two-Hybrid System and Its Role in Drug Discovery. *Expert Opin. Ther. Targets* 2008, 12 (4), 505–515.

(16) Braitu, G. G.; Venieris, E.; Kalousi, A.; Simos, G. Reconstitution of Human Hypoxia Inducible Factor HIF-1 in Yeast: A Simple in Vivo System to Identify and Characterize HIF-1α Effectors. *Biochem. Biophys. Res. Commun.* 2006, 346 (4), 1289–1296.

(17) Joshi, P. B.; Hirst, M.; Malcolm, T.; Parent, J.; Mitchell, D.; Lund, K.; Sadowski, I. Identification of Protein Interaction Antagonists Using the Repressed Transactivator Two-Hybrid System. *Biotechniques* 2007, 42 (5), 635–644.

(18) Hirst, M.; Ho, C.; Sabourin, L.; Rudnicki, M.; Penn, L.; Sadowski, I. A Two-Hybrid System for Transactivator Bait Proteins. *Proc. Natl. Acad. Sci. U. S. A.* 2001, 98 (15), 8726–8731.

(19) Cormack, B. P.; Valdivia, R. H.; Falkow, S. FACS-Optimized Mutants of the Green Fluorescent Protein (GFP). *Gene* 1996, 173 (1), 33–38.
(20) Brent, R.; Ptashne, M. A Eukaryotic Transcriptional Activator Bearing the DNA Specificity of a Prokaryotic Repressor. Cell 1985, 43 (3), 729–736.

(21) Ottzo, D. S. M.; Rudolf, F.; Stelling, J. Inducible, Tightly Regulated and Growth Condition-Independent Transcription Factor in Saccharomyces Cerevisiae. Nucleic Acids Res. 2014, 42 (17), e130.

(22) Rantasalo, A.; Kuivanen, J.; Penttilä, M.; Jäntti, J.; Mojtiza, D. Synthetic Toolkit for Complex Genetic Circuit Engineering in Saccharomyces Cerevisiae. ACS Synth. Biol. 2018, 7 (6), 1573–1587.

(23) Kalderon, D.; Roberts, B. L.; Richardson, W. D.; Smith, A. E. A Short Amino Acid Sequence Able to Specify Nuclear Location. Cell 1984, 39 (3), 499–509.

(24) Triezenberg, S. J.; Kingsbury, R. C.; McKnight, S. L. Functional Dissection of VP16, the Trans-Activator of Herpes Simplex Virus Immediate Early Gene Expression. Genes Dev. 1988, 2 (6), 718–729.

(25) Lee, M. E.; DeLoache, W. C.; Cervantes, B.; Dueber, J. E. A Highly Characterized Yeast Toolkit for Modular, Multpart Assembly. ACS Synth. Biol. 2015, 4 (9), 975–986.

(26) Chavez, A.; Scheiman, J.; Vara, S.; Pruitt, B. W.; Tuttle, M.; P R Iyer, E.; Lin, S.; Kiani, S.; Guzman, C. A.; Wiegand, D. J.; Ter-Ovanesyan, D.; Brafi, J. L.; Davidsohn, N.; Housden, B. E.; Perrimon, N.; Weiss, R.; Aach, J.; Collins, J. J.; Church, G. M. Highly Efficient Cas9-Mediated Transcriptional Programming. Nat. Methods 2015, 12 (4), 326–328.

(27) Tzamarias, D.; Struhl, K. Functional Dissection of the Yeast Cycl-Cyc8-Tup1 Transcriptional Co-Repressor Complex. Nature 1994, 369 (6483), 758–761.

(28) Treitel, M. A.; Carlson, M. Repression by SSN6-TUP1 Is Directed by MIG1, a Repressor/Activator Protein. Proc. Natl. Acad. Sci. U. S. A. 1995, 92 (8), 3132–3136.

(29) Gilbert, L. A.; Larson, M. H.; Morst, L.; Liu, Z.; Brar, G. A.; Torres, S. E.; Stern-Ginossar, N.; Brandman, O.; Whitehead, E. H.; Doudna, J. A.; Lim, W. J.; Weissman, J. S.; Qi, L. S. CRISPR-Mediated Modular RNA-Guided Regulation of Transcription in Eukaryotes. Cell 2013, 154 (2), 442–451.

(30) Schreiber-Agus, N.; Chin, L.; Chen, K.; Torres, R.; Rao, G.; Guida, P.; Skoultchi, A. I.; DePinho, R. A. An Amino-Terminal Domain of Mxi1Mediates Anti-Myc Oncogenic Activity and Interacts with a Homolog of the Yeast Transcriptional Repressor SIN3. Cell 1995, 80 (5), 777–786.

(31) Tavassoli, A. Hif-1 and Hif-2 Inhibitors. US20190033318A1, January 31, 2019.

(32) Erbel, P. J. A.; Card, P. B.; Karakuzu, O.; Bruick, R. K.; Gardner, K. H. Structural Basis for PAS Domain Heterodimerization in the Basic Helix–Loop–Helix-PAS Transcription Factor Hypoxia-Inducible Factor. Proc. Natl. Acad. Sci. U. S. A. 2003, 100 (26), 15504–15509.

(33) Shcherbakova, D. M.; Baloban, M.; Emelyanov, A. V.; Brenowitz, M.; Guo, P.; Verkhusha, V. V. Bright Monomeric Near-Infrared Fluorescent Proteins as Tags and Biosensors for Multiscale Imaging. Nat. Commun. 2016, 7 (1), 12405.

(34) Scott, L. H.; Mathews, J. C.; Flematti, G. R.; Filipovska, A.; Rackham, O. An Artificial Yeast Genetic Circuit Enables Deep Mutational Scanning of an Antimicrobial Resistance Protein. ACS Synth. Biol. 2018, 7 (8), 1907–1917.

(35) Kozak, M. Point Mutations Define a Sequence Flanking the AUG Initator Codon That Modulates Translation by Eukaryotic Ribosomes. Cell 1986, 44 (2), 283–292.

(36) Otto, M.; Skrekas, C.; Gossing, M.; Gustafsson, J.; Siewers, V.; David, F. Expansion of the Yeast Modular Cloning Toolkit for CRISPR-Based Applications, Genomic Integrations and Combinatorial Libraries. ACS Synth. Biol. 2021, 10 (12), 3461–3474.

(37) Lian, J.; HamedRad, M.; Hu, S.; Zhao, H. Combinatorial Metabolic Engineering Using an Orthogonal Tri-Functional CRISPR System. Nat. Commun. 2017, 8 (1), 1688.

(38) Berepiki, A.; Kent, R.; Machado, L. F. M.; Dixon, N. Development of High-Performance Whole Cell Biosensors Aided by Statistical Modeling. ACS Synth. Biol. 2020, 9 (3), 576–589.